These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2670209)

  • 1. A phase-II study of adoptive immunotherapy with continuous infusion of interleukin-2 in children with advanced neuroblastoma. A report on 11 cases.
    Favrot M; Floret D; Michon J; Negrier S; Bouffet E; Coze C; Gaspard M; Cochat P; Thiesse P; Andreu G
    Cancer Treat Rev; 1989 Jun; 16 Suppl A():129-42. PubMed ID: 2670209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation.
    Favrot MC; Floret D; Negrier S; Cochat P; Bouffet E; Zhou DC; Franks CR; Bijman T; Brunat-Mentigny M; Philip I
    Bone Marrow Transplant; 1989 Sep; 4(5):499-503. PubMed ID: 2790327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
    Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
    Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation.
    Soiffer RJ; Murray C; Gonin R; Ritz J
    Blood; 1994 Aug; 84(3):964-71. PubMed ID: 8043878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study.
    Pardo N; Martí F; Fraga G; Illa J; Badell I; Peiró M; Bertran E; García J; Rueda F; Cubells J
    Med Pediatr Oncol; 1996 Dec; 27(6):534-9. PubMed ID: 8888813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
    Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
    Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells.
    Thompson JA; Lee DJ; Lindgren CG; Benz LA; Collins C; Shuman WP; Levitt D; Fefer A
    Cancer Res; 1989 Jan; 49(1):235-40. PubMed ID: 2783243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of natural killer and lymphokine-activated killer (LAK) cell activity in vivo in patients treated with high-dose interleukin-2 and adoptive transfer of autologous LAK cells.
    Walewski J; Paietta E; Dutcher J; Wiernik PH
    J Cancer Res Clin Oncol; 1989; 115(2):170-4. PubMed ID: 2654134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-activated killer cells in the treatment of in-transit metastases from limb cutaneous melanoma.
    Vaglini M; Belli F; Santinami M; Arienti F; Parmiani G; Persiani L; Santoro N; Grazia Inglese M; D'Elia F; Cascinelli N
    Ann Surg Oncol; 1995 Jan; 2(1):61-70. PubMed ID: 7834457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia--a phase I study.
    Weisdorf DJ; Anderson PM; Blazar BR; Uckun FM; Kersey JH; Ramsay NK
    Transplantation; 1993 Jan; 55(1):61-6. PubMed ID: 8420066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.
    Bar MH; Sznol M; Atkins MB; Ciobanu N; Micetich KC; Boldt DH; Margolin KA; Aronson FR; Rayner AA; Hawkins MJ
    J Clin Oncol; 1990 Jul; 8(7):1138-47. PubMed ID: 2358835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-2 and lymphokine-activated killer cells in 15 children with advanced metastatic neuroblastoma.
    Negrier S; Michon J; Floret D; Bouffet E; Gentet JC; Philip I; Cochat P; Stamm D; Costil J; Gaspard M
    J Clin Oncol; 1991 Aug; 9(8):1363-70. PubMed ID: 1830096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): a pilot study in 19 patients.
    Blaise D; Viens P; Olive D; Stoppa AM; Gabert J; Pourreau CN; Attal M; Gaspard MH; Mannoni P; Jasmin C
    Eur Cytokine Netw; 1991; 2(2):121-9. PubMed ID: 1813015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective treatment of high-grade lymphoproliferative disorder after renal transplantation using autologous lymphocyte activated killer cell therapy.
    Li PK; Tsang K; Szeto CC; Wong TY; To KF; Leung CB; Lui SF; Yu S; Lai FM
    Am J Kidney Dis; 1998 Nov; 32(5):813-9. PubMed ID: 9820452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin 2 immunotherapy in children with neuroblastoma after high-dose chemotherapy and autologous bone marrow transplantation.
    Favrot MC; Michon J; Floret D; Cochat C; Negrier S; Mathiot C; Coze C; Zucker JM; Franks CR; Bouffet E
    Pediatr Hematol Oncol; 1990; 7(3):275-84. PubMed ID: 2206868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma.
    Kamani N; August CS; Bunin N; Leahey A; Bayever E; Goldwein J; Zusman J; Evans AE; Angio GD
    Bone Marrow Transplant; 1996 Jun; 17(6):911-6. PubMed ID: 8807093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer Group.
    Matthay KK; Seeger RC; Reynolds CP; Stram DO; O'Leary MC; Harris RE; Selch M; Atkinson JB; Haase GM; Ramsay NK
    J Clin Oncol; 1994 Nov; 12(11):2382-9. PubMed ID: 7964954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignancies.
    Fefer A; Robinson N; Benyunes MC; Bensinger WI; Press O; Thompson JA; Lindgren C
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S48-53. PubMed ID: 9457394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adoptive immunotherapy with interleukin 2 in oncology].
    Favrot M; Bouffet E; Négrier S; Combaret V; Philip I; Philip T
    Bull Cancer; 1990; 77(9):925-31. PubMed ID: 2224165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-2 in neuroblastoma: clinical perspectives based on biological studies.
    Rueda F; Martí F; Pardo N; Badell I; Peiró M; Bertran E; Villén E; García J; Cubells J
    Cancer Biother Radiopharm; 1996 Oct; 11(5):303-8. PubMed ID: 10851509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.